Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Robert M. Padilla"'
Autor:
Fabio Macciardi, Maria Giulia Bacalini, Ricardo Miramontes, Alessio Boattini, Cristian Taccioli, Giorgia Modenini, Rond Malhas, Laura Anderlucci, Yuriy Gusev, Thomas J. Gross, Robert M. Padilla, Massimo S. Fiandaca, Elizabeth Head, Guia Guffanti, Howard J. Federoff, Mark Mapstone
Publikováno v:
GeroScience, vol 44, iss 3
Recent reports have suggested that the reactivation of otherwise transcriptionally silent transposable elements (TEs) might induce brain degeneration, either by dysregulating the expression of genes and pathways implicated in cognitive decline and de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fed4f439d67051ab58e6db668f22f0e
https://hdl.handle.net/11585/901672
https://hdl.handle.net/11585/901672
Autor:
Alexander W Dromerick, Matthew A Edwardson, Dorothy F Edwards, Margot L Giannetti, Jessica eBarth, Kathaleen P Brady, Evan eChan, Ming T Tan, Irfan eTamboli, Ruth eChia, Michael eOrquiza, Robert M Padilla, Amrita K Cheema, Mark E Mapstone, Massimo S Fiandaca, Howard J Federoff, Elissa L Newport
Publikováno v:
Frontiers in Human Neuroscience, Vol 9 (2015)
Introduction: 795,000 Americans will have a stroke this year, and half will have a chronic hemiparesis. Substantial animal literature suggests that the mammalian brain has much potential to recover from acute injury using mechanisms of neuroplasticit
Externí odkaz:
https://doaj.org/article/756114495a934f7094d63c0edf56a88c
Autor:
Ricardo Miramontes, Thomas J. Gross, Mark Mapstone, Massimo S. Fiandaca, Robert M. Padilla, Fabio Macciardi, Amrita K. Cheema, Howard J. Federoff
Publikováno v:
Current topics in medicinal chemistry. 18(11)
Contemporary metabolomics experiments generate a rich array of complex high-dimensional data. Consequently, there have been concurrent efforts to develop methodological standards and analytical workflows to streamline the generation of meaningful bio
Publikováno v:
Open Journal of Genetics. :19-29
Medical and surgical therapies for patients with Parkinson’s disease (PD) are typically considered and initiated upon development of clinical signs, especially therapeutic gene transfer therapies. Early clinical trials delivering transgenes within